-- SynerFuse, Inc. made a significant impact as a Silver Sponsor and Exhibitor at the recently concluded Health 2.0 Conference, held from March 4–6, 2025, at the Luxor Hotel & Casino in Las Vegas. As a company leading the way in innovative integrative healthcare solutions, SynerFuse’s presence elevated the event’s dialogue around pain management, surgical innovation, and healthcare tech.
Established in 2018, SynerFuse emerged with a bold vision—combining spinal fusion with neuromodulation into a single procedure. This unique approach led to the development of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™), which was first successfully performed in 2022 at the University of Minnesota, M Health Fairview. By 2024, the company had completed a proof-of-concept study involving 15 e-TLIF™ procedures, showcasing promising clinical outcomes.
SynerFuse’s exhibit booth served as a hub for medical professionals, technologists, and healthcare leaders interested in transformative pain therapies. Attendees had the opportunity to learn about the company’s proprietary technique and the growing momentum behind its integrated spinal fusion and neuromodulation therapy. The team also shared insights on how their approach contributes to addressing the opioid crisis by offering alternative pain management strategies.
Justin Zenanko, CEO and Co-founder of SynerFuse, brought his wealth of corporate finance and entrepreneurial experience to the forefront during the conference. As a Certified Public Accountant with a background spanning corporate development and biotech finance, Justin has channeled his leadership toward revolutionizing surgical solutions for chronic low back pain. SynerFuse was recognized at the event with three prestigious honors: the “Excellence in Healthcare Award,” the “Visionaries Award,” and the “Outstanding Organization Award.”
Justin remarked on the experience, saying, “I'm honored to be part of the Health 2.0 Conference. Supporting this event aligns with SynerFuse’s commitment to advancing spine surgeries by reducing the need for opioids post-surgery. It was a privilege for myself and Dr. Rohan Lall, Chief Medical Officer of SynerFuse, contribute to such a meaningful gathering of industry leaders and visionaries. We look forward to continuing to support initiatives that drive innovation in health.”
As SynerFuse continues to build on its strong intellectual property portfolio and pursue clinical milestones, the company remains committed to delivering disruptive solutions that merge surgery and neuromodulation for better outcomes and improved lives. For more information about SynerFuse, Inc. and its e-TLIF™, an Ultra Low Energy™ (ULE™) Therapy, visit www.synerfuse.com.
Bringing together pioneers from healthcare, wellness, tech, and research, the Health 2.0 Conference stands out as a top-tier, three-day global event. Designed to spark collaboration and drive innovation, it addresses today’s toughest healthcare issues with actionable insights and advanced solutions. The conference is known for spotlighting transformative ideas and meaningful partnerships, with upcoming editions planned in both Dubai and the USA. Discover more at www.health2conf.com.
Contact Info:
Name: Bhawna Banga
Email: Send Email
Organization: Health 2.0 Conference
Website: https://www.health2conf.com/
Release ID: 89160574
Google
RSS